iCellate is a Swedish, privately owned, stock company founded in 2011 and based in Stockholm. iCellate develops products in the field of cancer research and detection, more specifically circulating tumor cells (CTC). iCellate® is based on research from the Karolinska Institute in collaboration with the Karolinska University Hospital and the Royal Institute of Technology in Stockholm. The company was inducted in the respected business incubator Stockholm Innovation and Growth (STING) in August 2011 and is supported by the Karolinska Institute’s Innovation Office. The company has received competitive business development grants from the Swedish Governmental Agency for Innovation Systems – VINNOVA, Uppsala Bio, Eurostars and the Swedish Incubators and Science Parks – SISP.